TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMDGet Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 54,900 shares, a drop of 57.7% from the January 15th total of 129,800 shares. Based on an average trading volume of 21,800 shares, the short-interest ratio is currently 2.5 days. Currently, 0.5% of the shares of the company are short sold.

Insider Activity

In related news, CEO Marlan D. Walker sold 14,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $2.31, for a total transaction of $33,495.00. Following the transaction, the chief executive officer now directly owns 67,115 shares of the company’s stock, valued at approximately $155,035.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On TherapeuticsMD

A number of large investors have recently added to or reduced their stakes in the stock. Clearline Capital LP grew its position in TherapeuticsMD by 8.6% during the second quarter. Clearline Capital LP now owns 455,372 shares of the company’s stock worth $1,876,000 after buying an additional 35,947 shares in the last quarter. BlackRock Inc. grew its stake in TherapeuticsMD by 18.1% during the second quarter. BlackRock Inc. now owns 137,127 shares of the company’s stock worth $565,000 after buying an additional 20,995 shares in the last quarter. Tejara Capital Ltd grew its stake in TherapeuticsMD by 3.9% during the second quarter. Tejara Capital Ltd now owns 369,594 shares of the company’s stock worth $1,523,000 after buying an additional 13,915 shares in the last quarter. State Street Corp grew its stake in TherapeuticsMD by 13.6% during the first quarter. State Street Corp now owns 30,130 shares of the company’s stock worth $113,000 after buying an additional 3,600 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in TherapeuticsMD by 22.2% during the first quarter. Geode Capital Management LLC now owns 81,781 shares of the company’s stock worth $307,000 after buying an additional 14,835 shares in the last quarter. Institutional investors and hedge funds own 28.68% of the company’s stock.

TherapeuticsMD Trading Down 1.7 %

Shares of TXMD stock traded down $0.04 on Monday, hitting $2.25. The company’s stock had a trading volume of 13,423 shares, compared to its average volume of 14,167. The stock’s 50 day moving average is $2.30 and its 200-day moving average is $2.80. TherapeuticsMD has a fifty-two week low of $1.95 and a fifty-two week high of $5.35.

TherapeuticsMD (NASDAQ:TXMDGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.13) EPS for the quarter. The business had revenue of ($0.05) million during the quarter. TherapeuticsMD had a net margin of 47.29% and a return on equity of 133.83%.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on TherapeuticsMD in a research report on Wednesday, February 7th. They issued a “hold” rating on the stock.

Check Out Our Latest Report on TXMD

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.

Featured Articles

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.